ConductScience.org, home
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
API referenceFor AI assistants

Trial · NCT02642159

Adverse events70

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 70

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherDiarrhoeaGastrointestinal disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W14275
otherDiarrhoeaGastrointestinal disordersUsual Care9137
otherBronchitisInfections and infestationsAlirocumab 75 mg Q2W/Up to 150 mg Q2W5275
otherBronchitisInfections and infestationsUsual Care7137
otherUrinary tract infectionInfections and infestationsAlirocumab 75 mg Q2W/Up to 150 mg Q2W15275
otherUrinary tract infectionInfections and infestationsUsual Care5137
otherArthralgiaMusculoskeletal and connective tissue disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W6275
otherArthralgiaMusculoskeletal and connective tissue disordersUsual Care8137
seriousAcute myocardial infarctionCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1275
seriousAcute myocardial infarctionCardiac disordersUsual Care1137
seriousAngina unstableCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W3275
seriousAngina unstableCardiac disordersUsual Care0137
seriousCoronary artery diseaseCardiac disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1275
seriousCoronary artery diseaseCardiac disordersUsual Care0137
seriousVertigoEar and labyrinth disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1275
seriousVertigoEar and labyrinth disordersUsual Care0137
seriousGlaucomaEye disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1275
seriousGlaucomaEye disordersUsual Care0137
seriousGastrooesophageal reflux diseaseGastrointestinal disordersAlirocumab 75 mg Q2W/Up to 150 mg Q2W1275
seriousGastrooesophageal reflux diseaseGastrointestinal disordersUsual Care0137

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02642159/events

API referenceFor AI assistants